- Home
- PETZ vs SNSE Comparison
PETZ vs SNSE Comparison
Compare PETZ & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- SNSE
- Stock Information
- Founded
- PETZ 2002
- SNSE 2005
- Country
- PETZ China
- SNSE United States
- Employees
- PETZ N/A
- SNSE N/A
- Industry
- PETZ Steel/Iron Ore
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- PETZ Industrials
- SNSE Health Care
- Exchange
- PETZ Nasdaq
- SNSE Nasdaq
- Market Cap
- PETZ 12.9M
- SNSE 12.5M
- IPO Year
- PETZ 2017
- SNSE 2021
- Fundamental
- Price
- PETZ $1.11
- SNSE $0.37
- Analyst Decision
- PETZ
- SNSE Strong Buy
- Analyst Count
- PETZ 0
- SNSE 4
- Target Price
- PETZ N/A
- SNSE $4.25
- AVG Volume (30 Days)
- PETZ 8.7K
- SNSE 8.1M
- Earning Date
- PETZ 04-28-2025
- SNSE 03-28-2025
- Dividend Yield
- PETZ N/A
- SNSE N/A
- EPS Growth
- PETZ N/A
- SNSE N/A
- EPS
- PETZ N/A
- SNSE N/A
- Revenue
- PETZ $3,278,453.00
- SNSE N/A
- Revenue This Year
- PETZ N/A
- SNSE N/A
- Revenue Next Year
- PETZ N/A
- SNSE N/A
- P/E Ratio
- PETZ N/A
- SNSE N/A
- Revenue Growth
- PETZ 2.46
- SNSE N/A
- 52 Week Low
- PETZ $1.03
- SNSE $0.25
- 52 Week High
- PETZ $1.74
- SNSE $1.94
- Technical
- Relative Strength Index (RSI)
- PETZ 32.84
- SNSE 38.86
- Support Level
- PETZ $1.10
- SNSE $0.25
- Resistance Level
- PETZ $1.41
- SNSE $0.76
- Average True Range (ATR)
- PETZ 0.09
- SNSE 0.07
- MACD
- PETZ -0.03
- SNSE -0.01
- Stochastic Oscillator
- PETZ 3.23
- SNSE 22.75
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling of petfood and restaurant operations. The company has two operating segments which include Petfood sales and Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.